At a glance
ClinicalIndex Comparison RecordN/ACompleted· 55 enrolled
Drug / intervention
Terumo Nanopass® 34G pen needle +1 moredevice
Likely dose
Terumo Nanopass® 34G pen needlefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparative User Experiences With BD Nano™ PRO 32G Extra Thin Wall Pen Needle vs the Terumo Nanopass® 34G Pen Needle
In Brief
A clinical study evaluating Terumo Nanopass® 34G pen needle and BD Nano™ PRO 32G pen needle for Diabetes. Completed, enrolled 55 participants across 2 sites.
Detailed Summary
This is a subject single blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. the thinner commercially available Terumo Nanopass® pen needle. The study will include a minimum of 55 Japanese American study subjects with Type 1 or Type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartFeb 2019
First PostedMar 2019
Primary CompletionJun 2019
TodayJul 2026
First PostedMar 18, 2019
Enrollment StartFeb 11, 2019
Primary CompletionJun 14, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 7.3 years ago
Interventions
Terumo Nanopass® 34G pen needledevice
Insulin pen needle
BD Nano™ PRO 32G pen needledevice
Insulin pen needle